<DOC>
	<DOCNO>NCT01794169</DOCNO>
	<brief_summary>The purpose study determine whether Azacitidine consolidation superior standard DA consolidation treatment acute myeloid leukemia first complete remission elderly patient .</brief_summary>
	<brief_title>Azacitidine Compared Conventional Chemotherapy Consolidation Elderly Patients With AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>1 . Subjects &gt; 65 year age time sign informed consent form 2 . A confirmed diagnosis AML accord 2008 WHO classification This include : Bone marrow aspirate good clot biopsy morphology , flow cytometry , cytogenetic analysis , case normal cytogenetics , molecular genetic analysis include FLT3ITD , NPM1 CEBP A Biobanking leukemic cell diagnosis perform ( accord guideline Swedish National AML biobank ) . 3 . A documented CR CRp achieve one two induction course . 1 . Subjects consider candidate complete consolidation therapy due medical psychological reason . 2 . Subjects take investigational drug participate interventional clinical trial within 30 day prior screen . 3 . Patients acute promyelocytic leukemia 4 . Patients ( 8 ; 21 ) inv ( 16 ) 5 . CNS leukemia 6 . Patients previous diagnosis MDS , i.e . AML precede diagnose MDS 7 . Subjects candidate allogeneic stem cell transplantation ( SCT ) 8 . Another cancer diagnosis life expectancy less two year</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>